Authors
Latest:
Dr Zakalik on the Role of Genetic Testing to Guide Breast Cancer TreatmentDana Zakalik, MD, discusses the critical role of genetic testing in managing breast cancer.
Latest:
Dr Bilusic on the Investigation of Enfortumab Vedotin in Rare GU CancersMarijo Bilusic, MD, PhD, discusses the investigation of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors.
Latest:
Dr. Kim on Tislelizumab in Advanced ESCCSunnie Kim, MD, contextualizes the use of tislelizumab as a frontline treatment option in advanced esophageal squamous cell carcinoma.
Latest:
Dr. Singh on the Potential Effects of Radiation Timing in Head and Neck CancerAnurag Singh, MD, discusses the potential effects of radiation timing in head and neck cancer.
Latest:
Dr Sharma on the Impact of Frontline Treatment Advances in Advanced Bladder CancerJanaki Neela Sharma, MD, discusses the implications of treatment advances in the front line for patients with advanced bladder cancer.
Latest:
Dr Desai on Unmet Needs With Chemoimmunotherapy in NSCLCakash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer.
Latest:
Dr Kenderian on the Efficacy of Liso-Cel in R/R CLL/SLLSaad J. Kenderian, MB, CHB, consultant, discusses the safety and efficacy findings derived from the phase 1/2 TRANSCEND CLL 004 study in CLL/SLL.
Latest:
Dr Wu on SAFFRON-301 Data in Advanced or Metastatic NSCLCYi-Long Wu, MD, PhD, discusses findings from the phase 3 SAFFRON-301 trial in patients with advanced or metastatic NSCLC.
Latest:
ASCP’s Outstanding Education Initiatives Receive Prestigious AwardsTwo innovative ASCP education initiatives have received accolades from the Alliance for Continuing Education in the Health Professions.
Latest:
Dr Singer on Toxicities Associated With First-Line IO/TKI Regimens in RCCAdam E. Singer, MD, PhD, discusses the safety profiles of immuno-oncology/TKI regimens in first-line renal cell carcinoma.
Latest:
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid TumorsSarwish Rafiq, PhD, discusses how engineering metabolically fit, memory rich CAR T-cells may address barriers to CAR T-cell efficacy in solid tumors.
Latest:
Dr Tripathi on the NEMIO Trial of Durvalumab Plus Chemo With/Without Tremelimumab in MIBCAbhishek Tripathi, MD, discusses the phase 1/2 NEMIO trial of durvalumab/chemotherapy with/without tremelimumab in muscle-invasive bladder cancer.
Latest:
Dr Peters on Vorasidenib in Residual or Recurrent IDH1/2-Mutant GliomaKatherine B. Peters, MD, PhD, discusses findings from the phase 3 INDIGO trial of vorasidenib in patients with recurrent or residual grade 2 glioma harboring an IDH1 or IDH2 mutation and how these results support the addition of vorasidenib to the treatment armamentarium.
Latest:
The Role of Genetics in Cancer Care Continues to ExpandGenetic screening and testing have only recently become an integral part of cancer care.
Latest:
Dr Ye on Early Efficacy Data for BL-B01D1 in Metastatic Urothelial CarcinomaDingwei Ye, MD, PhD, discusses the initial efficacy and safety of BL-B01D1 in locally advanced or metastatic urothelial carcinoma.
Latest:
Dr. Diamond on the Need to Integrate MRD Testing Into Clinical Trials in Multiple MyelomaBenjamin Diamond, MD, discusses the need to integrate minimal residual disease testing into clinical trials in multiple myeloma.
Latest:
Dr. Naing on the Potential Implications of Immune-Related Adverse Effects in CancerAung Naing, MD, FACP, discusses potential immune-related adverse effects in oncology.
Latest:
Dr McKean on the Efficacy of Fianlimab Plus Cemiplimab in Advanced MelanomaMeredith McKean, MD, discusses the efficacy of fianlimab given in combination with cemiplimab for patients with advanced melanoma.
Latest:
Women in Oncology: Self-Advocacy in a Busy FieldMelinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.
Latest:
Colorado School of Public Health Launches Innovative Program to Support Working Cancer PatientsThe Colorado School of Public Health announces the launch of WeCanWork, a program to provide support to cancer patients as they balance work and treatment.
Latest:
Clinical Insights: Looking Forward for pLGGThe leaders in the pediatric low-grade glioma (pLGG) field offer their concluding insights and perspectives on the future of pLGG management.
Latest:
CAR T-Cell Therapy in Metastatic CRPC and Future Directions in CareClosing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
Latest:
Dr Vidula on the Evaluation of Talazoparib in BRCA1/2-Mutated Metastatic Breast CancerNeelima Vidula, MD, discusses an ongoing phase 2 study evaluating the highly potent PARP inhibitor talazoparib in patients with somatic BRCA1/2-mutated metastatic breast cancer.
Latest:
Dr. Varga on Current Clinical Trials for Patients with Relapsed/Refractory Multiple MyelomaCindy Varga, MD, discusses several exciting clinical trials at the Levine Cancer Institute for patients with relapsed/refractory multiple myeloma with acquired resistance to BCMA-directed therapy.
Latest:
Dr. Schetelig on the Use of Induction Chemotherapy Prior to Allo-HCT in Relapsed/Refractory AMLJohannes Schetelig, MD, MSc, discusses whether patients with active relapsed/refractory acute myeloid leukemia (AML) should receive remission induction chemotherapy prior to undergoing allogenic hematopoietic stem cell transplant (allo-HCT).
Latest:
The Power of No, the Value of YesBrian I. Rini, MD, and Matthew Tucker, MD, sit down to discuss developing a career path and building a résumé, the value of writing review articles early in fellowship, the power of saying no, and the importance of saying yes.
Latest:
Dr Patel-Donnelly on Factors Influencing Consolidation Therapy in Hematologic MalignanciesDipti Patel-Donnelly, MD, discusses key factors to consider when selecting consolidation therapies in high-risk hematologic malignancies.
Latest:
Carving Out a Career in Medical EducationSam Brondfield, MD, MA, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses careers in medical education.
